La Jolla Pharma to be delisted after merger flop

La Jolla Pharmaceutical is running out of options.

Few shareholders bothered to even respond to its latest effort at a merger, and now the one-time high flyer says that its shares will be delisted from Nasdaq tomorrow. Its stock slid 5 cents this morning, chopping off 31 percent of its value as it slid to 11 cents a share. After today the company says its shares will be traded over the counter.

In a release, the company said that it wouldn't mount any new attempt to merge with Adamis. La Jolla suspended its work on Riquent a year ago. Nasdaq's move was triggered by its determination that the developer's nominal assets, aside from cash, and nominal operations qualified it as a 'public shell.'

- see La Jolla's release
- here's the AP report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.